Jones Financial Companies Lllp Purchases 971 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Jones Financial Companies Lllp boosted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCRFree Report) by 29.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,228 shares of the company’s stock after buying an additional 971 shares during the quarter. Jones Financial Companies Lllp’s holdings in Structure Therapeutics were worth $115,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Wellington Management Group LLP raised its holdings in Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock worth $341,015,000 after purchasing an additional 221,851 shares in the last quarter. FMR LLC raised its holdings in Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after purchasing an additional 383,635 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after purchasing an additional 820,589 shares in the last quarter. Finally, Vestal Point Capital LP raised its holdings in Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GPCR. JMP Securities restated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating for the company. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and an average price target of $81.29.

Read Our Latest Research Report on GPCR

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $21.05 on Friday. Structure Therapeutics Inc. has a 1-year low of $19.39 and a 1-year high of $62.74. The firm’s 50-day moving average price is $25.31 and its 200-day moving average price is $32.38. The company has a market capitalization of $1.21 billion, a PE ratio of -28.45 and a beta of -2.35.

Structure Therapeutics (NASDAQ:GPCRGet Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

About Structure Therapeutics

(Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Read More

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. (NASDAQ:GPCRFree Report).

Institutional Ownership by Quarter for Structure Therapeutics (NASDAQ:GPCR)

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.